GLP-1 & Incretin Science

SURMOUNT-OSA: Tirzepatide in Obstructive Sleep Apnoea

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

SURMOUNT-OSA tested tirzepatide in adults with moderate-to-severe obstructive sleep apnoea and obesity across two 52-week studies. In participants not using positive airway pressure, mean apnoea-hypopnoea index fell 27.4 events per hour against 4.8 on placebo, a 55.0% reduction against 5.0%.

Key facts

Trial
SURMOUNT-OSA, two 52-week studies
Publication
NEJM, October 2024 (PMID 38912654)
Study 1 population
Not using PAP therapy
Study 1 AHI reduction
27.4 events/hour vs 4.8 placebo
Study 1 percentage
55.0% vs 5.0%
Study 2 (on PAP)
30.4 events/hour vs 6.0 placebo
Weight reduction
18.1% vs 1.3% (Study 1)
Estimand
Efficacy estimand

Why sleep apnoea is a coherent target

Obstructive sleep apnoea occurs when the upper airway collapses repeatedly during sleep. Excess soft tissue around the airway is one contributor, and body weight is strongly associated with severity. A compound producing 18% weight reduction therefore has a plausible mechanical route to reducing apnoea severity. This is a fairly direct consequence rather than an unexpected pleiotropic effect.

What AHI measures

The apnoea-hypopnoea index counts breathing interruptions per hour of sleep. Roughly, 5 to 15 is mild, 15 to 30 moderate and above 30 severe. Because it is an event rate rather than a symptom score, a change of 27.4 events per hour is a large absolute movement, enough to shift a participant across severity categories rather than within one.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The two studies and why they were split

Study 1 enrolled participants not using positive airway pressure therapy; Study 2 enrolled those using PAP and continuing it. Splitting them matters because PAP is an effective existing treatment, and a drug's contribution on top of PAP is a different question from its effect in people not using it. Study 2 reported a mean AHI reduction of 30.4 events per hour against 6.0 on placebo.

What else moved

Beyond AHI and body weight, the published results reported reductions in hypoxic burden, high-sensitivity C-reactive protein and systolic blood pressure, alongside improvement in sleep-related patient-reported outcomes. The last of those matters most clinically: an event-rate improvement that patients do not notice would be a weaker result than one they report feeling.

The estimand, again

The reported figures are for the efficacy estimand (participants adhering to treatment), which the release states explicitly. As with CagriSema's 22.7% and SURMOUNT-1's 22.5%, quoting the figure without naming the estimand overstates what a treatment-policy analysis would show. The consistency of this pattern across the field is why it should be checked every time.

Why this approval mattered

It moved an incretin into a non-metabolic indication with an objective, instrument-measured endpoint. AHI is recorded by polysomnography, not reported by the participant, which makes it harder to attribute to expectation effects than a symptom questionnaire. That strengthens the broader case that weight reduction at this magnitude produces measurable downstream change.

Quick reference

Endpoint (52 wks)TirzepatidePlacebo
AHI reduction, Study 127.4 events/hr4.8 events/hr
AHI percentage, Study 155.0%5.0%
AHI reduction, Study 230.4 events/hr6.0 events/hr
Body weight, Study 1−18.1%−1.3%

Frequently asked questions

Does tirzepatide cure sleep apnoea?

The trials report large reductions in apnoea-hypopnoea index, not elimination. Mean AHI fell substantially but participants were not reported as free of the condition.

Is the benefit just from weight loss?

Weight reduction is the most plausible route, given the mechanical relationship between soft tissue around the airway and apnoea severity. The trials were not designed to separate the two.

Why were there two studies?

One enrolled participants using positive airway pressure therapy and one did not. A drug's effect on top of an existing effective treatment is a different question from its effect alone.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.